Conclusions:
Pease et al studied RA at onset 60 years and over and PMR, and reported that arthritis of wrists and fingers was suggestive of RA 1 . However, in our study, small joint swelling was rare in RA patients 75 years and older. The scoring system we made might be useful for the differential diagnosis of ACPA-negative RA and PMR in elderly patients 75 years and older. Background: Patients with Rheumatoid Arthritis (RA) have an increased risk for cardiovascular disease (CVD) due to higher prevalence of traditional risk factors (1), Insulin resistance (IR) is implicated in inflammatory diseases such as RA (2). The prevalence of Met.Syn and IR in Egyptian female RA patients has not been studied before. Objectives: To find out the prevalence of Met.Syn and IR in a cohort of Egyptian females with RA and in controls and to study the associated risk factors Methods: 60 female RA patients and 30 healthy females matched for age were included according to the ACR/EULAR 2010 classification criteria. Disease activity was assessed using DAS-28. IR using HOMA-index (HOMA-IR) (3) Met.Syn was defined according to the updated third report of the National Cholesterol Education Program's Adult Treatment Panel (NCEP-ATP III) criteria (4 Background: Planning a pregnancy in rheumatoid arthritis (RA) meets several issues, mostly concerning potential drug toxicity and disease flares Objectives: The purpose of this study is to evaluate pregnancy planning, RA activity during pregnancy and postpartum, pregnancy and fetal outcomes in a Romanian cohort of female patients diagnosed with RA. Methods: This is an observational, ambispective study, including 58 RA Caucasian females with obstetric history after the onset of RA (20 females -prospective, 38 -retrospective). The cases were obtained from several Clinics of Rheumatology from Romania Results: The mean age at inclusion was 37.1 years, age at RA diagnosis 3.9 years and mean age at conception 32.2 years. We recorded a total number of 96 pregnancies: 48 deliveries at term, 4 premature births, 15 elective abortions, 24 spontaneous abortions, and 5 ongoing. 34/96 (35.4%) had at least one unplanned pregnancy, while being on treatment. Concerning the exposure to synthetic DMARDs during the pregnancy: 6 patients received Leflunomide and 4 received Methotrexate during the first trimester, the pregnancy outcomes being: 3 spontaneous and 3 elective abortions, 3 normal birth (1-Cholestiramine wash-out), 1 premature twin pregnancy. Regarding biologic DMARDs: 5 were exposed to Etanercept -3 less than 3 weeks, (2 normal births and one elective abortion-due to Methotrexate use), 2 treated in second trimester: 1 only in the 15th and 16th weeks due to relapsenormal birth, and the other one until week 20, pregnancy still ongoing. One patient was treated with Certolizumab until week 12, the pregnancy is ongoing, and one with Adalimumab until week 4, the fetus had intrauterine growth restriction, premature birth. 6 patients treated with Rituximab were included, last infusions were: 4 weeks before conception (1-spontaneous abortion and 1 normal birth), 48 weeks (2 normal births and 1 premature), and one at 4 weeks after conception -normal birth. In 4 cases the patients stopped the biological DMARD before conception: Etanercept 6 months and 2 years, Adalimu-mab,6 months with normal outcome, and for Tocilizumab 9 months (growth restriction) 81.25% of our patients were in Remission or Low Disease Activity (by DAS28CRP) at conception and generally this status was maintained, excepting several situations. Background: Ultrasound (US) is able to show subclinical synovitis in patients (pts) with rheumatoid arthritis (RA) who are in clinical remission (CR); this has been proposed as a predictive factor for both clinical flares and progression of the structural damage in CR pts. Objectives: To investigate the US characteristics of RA pts presenting either CR or low disease activity (LDA). Methods: In 2015 an educational event focused on the added value of US in RA pts was held in 22 rheumatology centers in Italy. After a brief presentation on the evidence of US added value for the clinician given by expert sonographers (rheumatologists with a special interest in US that were performing US as their usual activity for many years), in every center, the local rheumatologists provided RA pts to be examined by US. All the US machines were identical both for type (Logiq E R7, General Electrics, with a 4.2-13 MHz linear probe) and settings (both for grey-scale and power Doppler (PD)). Pts signed an informed consent and a brief history of them was collected by the local rheumatologists (previous and current therapy, DAS28, HAQ score). The US examination was performed bilaterally on wrists, MCP and MTP joints, looking for synovitis (effusion, synovial proliferation and PD signal) and bone erosions. The positive findings were scored according to a 0-3 score for synovitis components and presence/absence for erosions; the number and size of the largest erosion was also registered. Results: Demographic and descriptive data of the 433 pts examined are reported in Table I . Pts were divided on the basis of the DAS28 result. Statistically significant differences in age and disease duration were registered between the group in CR and the group with DAS28≥3.2 (p=0,019 and p=0,012, respectively), while no differences were found for HAQ or MTX use. Higher positivity of findings, regardless which was the score, was present in LDA group for effusion, synovial proliferation and PD signal. Significant differences were seen between CR and LDA group for effusion (general, MCP and MTP joints; p=0, 011, p=0, 026, p=0, 017 and p=0, 013, respectively), PD positivity (general, wrist, MCP and MTP joints; p=0, 006, p=0, 023 and p=0, 05, respectively) and erosions (p=0,002), with higher positivity for pts in LDA. Conclusions: The US assessment in this large cohort of RA pts showed frequent positive findings both in the CR and in the LDA group, confirming the results from previous studies. US is a useful imaging tool for the detection of subclinical joint abnormalities in RA. Background: Patients with active rheumatoid arthritis (RA) are frequently diagnosed with an atherogenic lipid profile and supra-aortic vessel ultrasound signs of atheromatous plaques, which have been linked to the inflammatory activity of RA. Recent experimental and clinical evidences suggest that the beneficial effects of statins are pleiotropic and have been proposed to have anti-inflammatory and immunomodulatory effects, inhibiting proinflammatory cytokines (IL-1β, 6, 8, TNF-α), adhesion molecules (sICAM 1, E-, P-selectin), osteoprotegerin, which are implicated in RA pathogenesis. However, the beneficial role of statin therapy in clinical improvement and their benefit-risk profile are still debatable. Objectives: To evaluate the effect of medium-term rosuvastatin therapy on lipid profile, endothelial dysfunction and RA activity in patients with rheumatoid arthritis (RA) in comparison with conventional disease modifying antirheumatic drugs (DMARD) therapy. Methods: The study included 82 patients in the Specialized Course Outpatient Therapy Department of the 1st Clinic of Tashkent Medical Academy of age group between 44 and 65 years (mean 52±8.4), predominantly female gender (n=57, 69.5%), with early RA (mean disease duration 9.2±2.4 months), and divided into 2 groups. Group 1 (n=40) received methotrexate (MTX; 7.5 mg/week; plus prednisolone (10 mg/day). Group 2 (n=42) received MTX and prednisolone with the same previous doses plus rosuvastatin (40 mg/day). Lipid profile assessment comprised triglycerides, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C). Disease activity was assessed by the disease activity score of 28 joints (DAS28), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and visual analog scale (VAS). Disease activity, lipid profile and intima-media thickness (IMT) of common carotid arteries were measured before and after 85 days (6 months) of treatment. Results: 4 patients receiving rosuvastatin were excluded due to abnormal liver function test parameters (De Ritis ratio <0.9), further assessment was thus performed on 78 (Group 2, n=38) early RA patients. Overall ESR (Group 1: 24.4±7.26; Group 2: 37.4±12.3) and CRP (Group 1: 5.56±0.58; Group 2: 3.71±1.23) declined significantly during the treatment. The mean DAS28, unconditionally considered as the most important index of clinical disease activity in RA, was found to be lower (p<0.05) in the adjunct statin-treated group (Group 2: 3.68±0.77) than that of the conventional DMARD treated group (Group 1: 4.45±1.08). Statin significantly reduced LDL-C (3.9±1.2 mmol/l to 3.3±0.8 mmol/l; p=0.08) and increased HDL-C (1.3±0.6 mmol/l to 2.0±0.4 mmol/l; p=0.06) after 6 months of treatment. However, rosuvastatin therapy showed no significant improvement in VAS score (6.7±1.5 to 6.9±0.6; p=0.41) and IMT (1.04±0.09 to 1.08±0.07; p=0.05). Conclusions: Statins ameliorate RA activity, reduce potential cardiovascular risk in the context of atherosclerosis and mediate clinically apparent anti-inflammatory effects, but long-term effects and benefit-risk profile should be addressed in the management of elevated risk of cardiovascular events in RA patients. Background: Early change in body composition is one of the risk factors of CVD in rheumatoid arthritis (RA). These changes have been atributed to inflammation and decreased physical activity. Glucocorticosteroids (GCS) reduces inflammation but may influence body composition. There is limited information about the effects of low-dose GCS on body composition in early RA. Objectives: The aim of the study was to assess the presence of altered body composition in patients with early rheumatoid arthritis (eRA) and to determine whether low-dose prednisone affects body composition. Methods: 65 consecutive eRA patients (49 women) aged 61±14 years were assessed at the time of diagnosis and after 12 months of treatment. All the patients had been treated with methotrexate (target dose 25-30mg/week) and tapered doses of prednisone (mean dose 4.8±3.4 mg/day). Disease activity score (DAS28), Health Assesment Questionnaire (HAQ), body mass index (BMI), waist/hip ratio, comorbidities, physical activity and smoking were recorded. Total and regional lean mass and fat mass were measured with dual energy X-ray absorptiometry (DXA). DXA measures were repeated after 12 months in 34 patients (24 women) and compared with baseline data. Results: At baseline fat free mass index (FFMI; kg/m 2 ) was below the 10th percentile of a reference population in 32% of the women and 25% of the men. Reduced FFMI correlated with baseline ESR. Fat mass index (FMI) was above 90th percentile in 28% of the women and 42% of the men. Fat mass index (FMI;kg/m 2 ) correlated with HAQ, age and femoral BMD in women. After 12 months FFMI and FMI did not change significantly. There was no correlation between prednisone doses and the duration of prednisone treatment and changes in regional lean mass and fat mass. The decrase of FFMI (in 16 patients) was associated with higher mean ESR and lower vitamin D3 serum concentration. Conclusions: Low FFMI was common in patients with eRA. The treatment with
